PharVision Advisers’s Comstock Resources CRK Stock Holding History

PharVision Advisers’s Portfolio CRK Stock Details CRK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-16,171	Closed	-$295K	–	320
2024 Q4	$295K	Buy	+16,171	New	+$224K	0.25%	164

Other funds holding CRK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return

PharVision Advisers's CRK Position: Q1 2025 in Review

PharVision Advisers sold out of Comstock Resources (CRK) in Q1 2025, closing a stake of 16,171 shares — an estimated $295K sold.

PharVision Advisers first reported a position in CRK in Q4 2024 and held it in 1 quarter. The position peaked at $295K in Q4 2024. 279 funds tracked by Wall St. Rank hold CRK as of Q1 2025.

PharVision Advisers reported no remaining Comstock Resources position as of Q1 2025 after selling out during the quarter.
PharVision Advisers sold 16,171 Comstock Resources shares in Q1 2025, an estimated $295K.
PharVision Advisers first reported a position in Comstock Resources in Q4 2024 and held it in 1 quarter.
PharVision Advisers's Comstock Resources position peaked at $295K in Q4 2024.
279 funds tracked by Wall St. Rank held Comstock Resources as of Q1 2025.

Based on PharVision Advisers's 13F filing for Q1 2025, filed 15 May 2025.